JP Morgan Upgrades BioNTech to Neutral, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has upgraded BioNTech (NASDAQ:BNTX) from Underweight to Neutral and increased the price target from $91 to $125.
September 16, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has upgraded BioNTech from Underweight to Neutral, raising the price target to $125. This suggests a more positive outlook on the stock.
The upgrade from Underweight to Neutral by a major financial institution like JP Morgan indicates increased confidence in BioNTech's stock performance. The raised price target to $125 suggests potential upside, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100